The Centre’s Department of Pharmaceuticals is inviting drugmakers to apply for a production linked incentive (PLI) scheme.
The scheme encourages setting up new manufacturing capacity for 11 key pharmaceutical products like Neomycin, Gentamycin, and Ciprofloxacin.
These products are either unsubscribed or partially subscribed in previous PLI rounds.
Conditions include limits on incentives, allocation based on capacity, and incentives lasting until FY28 for chemical products and FY29 for fermentation-based products.
Companies that withdrew or lost approval earlier cannot apply again.
The Pharmaceuticals Export Promotion Council of India is urging its members to use this opportunity.
The scheme aims to boost domestic manufacturing of critical pharmaceutical materials like key starting materials (KSMs), drug intermediates (DIs), and active pharmaceutical ingredients (APIs).
India started PLI schemes four years ago for 14 key sectors to increase production, jobs, and exports.
The pharma scheme covers 41 products with a budget of ₹6,940 crore.
By March 2025, 764 applications were approved under PLI for 14 sectors, with investments of ₹1.61 lakh crore and incentives of ₹14,020 crore disbursed.
Sectors covered include electronics, IT hardware, bulk drugs, medical devices, food processing, automobiles, drones, and more.
COMMENTS